| Name | Date Acquired | How Acquired | Date Sold | Purchaser Name | Gross Sales Price | Basis | Basis Method | Sales Expenses | Total (net) | Accumulated Depreciation |
|---|---|---|---|---|---|---|---|---|---|---|
| PARTNERSHIP FLOWTHROUGH - UBI - LONG-TERM | PURCHASED | 2019-06 | 37,252 | 0 | 37,252 | |||||
| PARTNERSHIP FLOWTHROUGH - UBI SHORT-TERM | PURCHASED | 2019-06 | 10,489 | 0 | -10,489 |
| Identifier | Return Reference | Explanation |
|---|---|---|
| DONOR ADVISED FUNDS | FORM 990-PF, PART VII-A, LINE 12 | CONTRIBUTIONS TOTALING $922,000 WERE MADE BETWEEN JULY 1, 2018 AND JUNE 30, 2019 TO A DONOR ADVISED FUND AT CHATTANOOGA CHRISTIAN COMMUNITY FOUNDATION (DBA THE GENEROSITY TRUST), EIN# 62-1536731; WITH $922,000 BEING DISTRIBUTED IN THE SAME FISCAL YEAR. THE TRUST RETAINED ADVISORY PRIVILEGES. CHATTANOOGA CHRISTIAN COMMUNITY FOUNDATION ("CCCF") IS A SECTION 509(A)(1) ORGANIZATION AS REFERRED TO IN SECTION 170(B)(1)(A)(VI). THE ENTIRE AMOUNT WAS TREATED AS A QUALIFYING DISTRIBUTION IN PART XV, LINE 3, CONTRIBUTIONS, GIFTS, GRANTS PAID (STATEMENT #16). THE DONOR-ADVISED FUND AGREEMENT BETWEEN THE HUGH AND CHARLOTTE MACLELLAN CHARITABLE TRUST AND CCCF INCLUDES THE FOLLOWING:"CCCF SHALL RECEIVE, REVIEW AND CONSIDER WRITTEN RECOMMENDATIONS FROM THE COMMITTEE CONCERNING GRANTS MADE FROM THE FUND AND ANY CONDITIONS WHICH SHOULD BE PLACED UPON SUCH GRANTS. THE FINAL DECISION CONCERNING SUCH MATTERS SHALL BE MADE BY THE BOARD OF DIRECTORS OF CCCF.""NO INCOME OR PRINCIPAL OF THE FUND SHALL BE USED FOR ANY PURPOSE OR PAID TO ANY BENEFICIARY IF SUCH USE OR PAYMENT WOULD NOT BE PERMITTED BY THE INTERNAL REVENUE CODE (THE "CODE") OR REGULATIONS THEREUNDER FOR AN ORGANIZATION DESCRIBED IN SECTION 501(C)(3) OF THE CODE, TO WHICH CONTRIBUTIONS ARE DEDUCTIBLE UNDER SECTION 170(C)(2) OF THE CODE." |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| AEGEA MEDICAL INC. | 750,000 | 750,000 |
| ATLANTA CATHETER THERAPIES | 58,620 | 47,379 |
| VERAN MEDICAL TECHNOLOGIES | 462,528 | 497,130 |
| COHERA MEDICAL | 1,291,259 | 1,330,779 |
| NXTHERA | 8,110 | 8,110 |
| NXPHASE | 0 | 642,513 |
| PERSHING 2076 | 4,826,680 | 4,984,076 |
| PERSHING 3036 | 1,223,699 | 1,280,850 |
| PERSHING 6151 | 749,526 | 975,305 |
| PERSHING 2145 | 496,468 | 599,344 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| AERIAL BIOPHARMA, LLC | AT COST | 196,110 | 1,521,583 |
| ALTUM CREDIT FUND, L.P. | AT COST | 1,770,771 | 2,091,744 |
| ARRIVO BIOVENTURES, LLC | AT COST | 171,626 | 171,436 |
| BOW RIVER CAPITAL 2017-QP FUND, LP | AT COST | 162,070 | 130,023 |
| C-III RECOVERY FUND II LP | AT COST | 340,601 | 358,251 |
| CEVIAN CAPITAL II, LP | AT COST | 1,069,005 | 1,012,312 |
| DYNAMO FUND I, LP | AT COST | 430,523 | 368,179 |
| FULCRUM GROWTH FUND III QP, LLC | AT COST | 326,862 | 273,783 |
| GCM GROSVENOR MACLELLAN INVESTMENT FUND LP | AT COST | 33,666 | 141,201 |
| H20EY | AT COST | 94,593 | 94,593 |
| KERN MEDICAL IV, LLC | AT COST | 150,000 | 150,000 |
| KERN ODYSSEUS LLC | AT COST | 100,000 | 100,000 |
| KW STRATUS, LLC | AT COST | 216,432 | 216,432 |
| MIDNIGHT PHARMA, LLC | AT COST | 15,394 | 12,607 |
| NORTH AVENUE CAPITAL, LLC | AT COST | 500,000 | 500,000 |
| PS INSTITUTIONAL ONSHORE LP | AT COST | 1,005,384 | 885,087 |
| PORTFOLIO ADVISORS SECONDARY FUND III, L.P. | AT COST | 439,748 | 443,568 |
| RELEVANCE CAPITAL III LP | AT COST | 474,537 | 473,719 |
| RENAISSANCE INSTITUTIONAL EQUITIES FUND LLC | AT COST | 1,523,538 | 1,706,367 |
| RESOLUTE CAPITAL PARTNERS FUND IV, L.P. | AT COST | 347,755 | 247,755 |
| RESOURCE LAND FUND, III, LLC | AT COST | 141,782 | 154,268 |
| RIVER V, L.P. | AT COST | 0 | 118,723 |
| RIVER VI, L.P. | AT COST | 280,591 | 319,681 |
| RIVER VII | AT COST | 371,067 | 261,457 |
| TENTH STREET FINANCIAL OPPORTUNITY FUND II, L.P. | AT COST | 79,080 | 86,314 |
| SIGNIA VENTURE PARTNERS III, LP | AT COST | 37,660 | 15,347 |
| VALOR VENTURE FUND II LP | AT COST | 583,553 | 333,553 |
| GOLUB PARTNERS INTERNATIONAL | AT COST | 1,069,331 | 1,069,331 |
| HARBINGER CAPITAL PARTNERS SPECIAL SITUATIONS OFFSHORE LP | AT COST | 380,714 | 27,973 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| CHAMBLISS, BAHNER & STOPHEL, P.C. | 12,370 | 6,185 | 6,185 |
| Description | Beginning of Year - Book Value | End of Year - Book Value | End of Year - Fair Market Value |
|---|---|---|---|
| PARTNERSHIP DISTRIBUTIONS RECEIVABLE | 0 | 376,867 | 376,867 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| MANAGEMENT FEES THROUGH BROKERS | 45,791 | 45,791 | 0 | |
| PORTFOLIO DEDUCTIONS THROUGH PARTNERSHIPS | 104,674 | 104,674 | 0 | |
| INVESTMENT INTEREST THROUGH PARTNERSHIPS | 24,268 | 24,268 | 0 | |
| OTHER PARTNERSHIP DEDUCTIONS | 177,983 | 177,983 | 0 | |
| NON DEDUCTIBLE EXPENSES THROUGH PARTNERSHIPS | 737 | 0 | 0 | |
| OTHER PARTNERSHIP MANAGEMENT FEES | 433 | 433 | 0 | |
| OFFICE EXPENSE REIMBURSEMENTS | 28,993 | 0 | 28,993 | |
| BANK CHARGE & WIRE FEE | 810 | 608 | 202 | |
| SECTION 965(C) DEDUCTION | 36 | 36 | 0 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| TAX EXEMPT INCOME | 385 | 0 | 385 |
| PARTNERSHIPS ORDINARY INCOME | 45,154 | 45,154 | 45,154 |
| PARTNERSHIPS ROYALTIES | 5 | 5 | 5 |
| PARTNERSHIPS OTHER PORTFOLIO INC | 72,320 | 72,320 | 72,320 |
| PARTNERSHIPS OTHER INCOME | 194,190 | 194,190 | 194,190 |
| UNRELATED BUSINESS INCOME | -29,471 | -29,471 | |
| SECTION 965(A) INCOME INCLUSION | 72 | 72 | 72 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FOREIGN TAX WITHHELD FROM INCOME | 6,595 | 6,595 | 0 | |
| FOREIGN TAX WITHHELD THROUGH PARTNERSHIPS | 9,581 | 9,581 | 0 | |
| FEDERAL AND STATE EXCISE TAX | 2,405 | 0 | 0 |